Display options
Cite
Chung CC, Kao YH, Liou JP, et al. Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix. Acta Cardiol Sin. 2014;30(5):474-82
Chung, C. C., Kao, Y. H., Liou, J. P., & Chen, Y. J. (2014). Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix. Acta Cardiologica Sinica, 30(5), 474-82.
Chung, Cheng-Chih, et al. "Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix." Acta Cardiologica Sinica vol. 30,5 (2014): 474-82.
Chung CC, Kao YH, Liou JP, Chen YJ. Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix. Acta Cardiol Sin. 2014 Sep;30(5):474-82. PMID: 27122821; PMCID: PMC4834960.
Copy Download .nbib Format: NLM
Share it on

Acta Cardiol Sin. 2014 Sep;30(5):474-82.

Curcumin Suppress Cardiac Fibroblasts Activities by Regulating Proliferation, Migration, and the Extracellular Matrix.

Acta Cardiologica Sinica

Cheng-Chih Chung, Yu-Hsun Kao, Jing-Ping Liou, Yi-Jen Chen

Affiliations

  1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University; ; Division of Cardiovascular Medicine, Department of Internal Medicine;
  2. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University; ; Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University;
  3. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.

PMID: 27122821 PMCID: PMC4834960

Abstract

BACKGROUND: Cardiac fibrosis plays a critical role in the pathophysiology of cardiovascular disease. It has been observed that curcumin has several cardiovascular effects. The purpose of this study was to evaluate whether curcumin can attenuate cardiac fibroblasts activity.

METHODS AND RESULTS: We evaluated the migration, proliferation, collagen production, and transcription signaling in rat cardiac fibroblasts isolated from Sprague-Dawley rats (males, weighing 300-350 g) that were or were not incubated with curcumin (25 μM) and the co-administration of transforming growth factor (TGF)- β1 (10 ng/ml) or angiotensin (Ang) II (100 nM) by a cell migration analysis, proliferation assay, and Western blot analysis. Compared to those without curcumin, curcumin-treated cardiac fibroblasts exhibited lower migratory, proliferative abilities and collagen production at the baseline and after the co-administration of TGF-β1 or Ang II. Curcumin-treated cardiac fibroblasts had increased matrix metalloproteinase (MMP)-2 activity in the presence of Ang II treatment. Curcumin-treated cardiac fibroblasts down-regulated phosphorylated protein kinase B (Akt) and phosphorylated Smad2/3 expression irrespective of TGF-β1 treatment. Curcumin also decreased phosphorylated extracellular signal-regulated kinase (ERK)1/2 levels in the presence of Ang II.

CONCLUSIONS: Curcumin attenuated Akt, Smad2/3, and ERK1/2 phosphorylation which were mediated by TGF-β1 and angiotensin II. This resulted in decreased cardiac fibroblast activation and supports the assertion that curcumin is an effective antifibrotic agent which can be used to treat heart failure.

KEY WORDS: Angiotensin; Curcumin; Fibroblasts; Heart failure; Transforming growth factor.

References

  1. Circulation. 2000 Nov 28;102(22):2700-6 - PubMed
  2. Biol Pharm Bull. 2004 Feb;27(2):198-202 - PubMed
  3. Br J Pharmacol. 2003 Aug;139(7):1342-50 - PubMed
  4. Cardiovasc Res. 2005 Jan 1;65(1):40-51 - PubMed
  5. Mech Ageing Dev. 2000 Apr 14;114(3):207-10 - PubMed
  6. Circ Res. 2002 Dec 13;91(12):1119-26 - PubMed
  7. Circ Res. 1988 Apr;62(4):757-65 - PubMed
  8. J Mol Cell Cardiol. 2005 Oct;39(4):699-707 - PubMed
  9. Br J Pharmacol. 2010 Nov;161(5):1137-49 - PubMed
  10. Acta Cardiol. 2007 Oct;62(5):429-38 - PubMed
  11. Am J Physiol Lung Cell Mol Physiol. 2010 May;298(5):L616-25 - PubMed
  12. Chem Pharm Bull (Tokyo). 1993 Sep;41(9):1640-3 - PubMed
  13. Nature. 2003 Oct 9;425(6958):577-84 - PubMed
  14. Am J Hypertens. 2008 Oct;21(10):1129-36 - PubMed
  15. J Mol Cell Cardiol. 1995 Jun;27(6):1281-92 - PubMed
  16. Annu Rev Pharmacol Toxicol. 2005;45:657-87 - PubMed
  17. Hypertension. 2000 Sep;36(3):330-6 - PubMed
  18. J Cell Biol. 1993 Jul;122(1):103-11 - PubMed
  19. J Mol Cell Cardiol. 2006 Jul;41(1):97-107 - PubMed
  20. Nutr Metab (Lond). 2006 Jul 18;3:27 - PubMed
  21. Br J Pharmacol. 2012 Dec;167(7):1550-62 - PubMed
  22. J Cardiovasc Pharmacol. 2010 Apr;55(4):417-24 - PubMed
  23. J Clin Invest. 1994 Jun;93(6):2372-8 - PubMed
  24. PLoS One. 2012;7(9):e44946 - PubMed
  25. J Clin Invest. 2008 Mar;118(3):868-78 - PubMed
  26. Indian J Med Res. 1982 Apr;75:574-8 - PubMed
  27. Pharmacol Ther. 2009 Aug;123(2):255-78 - PubMed
  28. Int J Cardiol. 2013 Oct 9;168(4):4178-83 - PubMed
  29. Circulation. 2008 Apr 1;117(13):1630-41 - PubMed
  30. Eur Heart J. 2012 Sep;33(18):2360-9 - PubMed
  31. Circ Res. 2010 Jun 11;106(11):1675-80 - PubMed
  32. Circulation. 2003 Sep 16;108(11):1395-403 - PubMed
  33. Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G20-30 - PubMed
  34. Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G113-23 - PubMed
  35. Crit Care Med. 2010 Jan;38(1):217-22 - PubMed
  36. Basic Res Cardiol. 1999 Dec;94(6):464-71 - PubMed
  37. J Mol Cell Cardiol. 1994 Jul;26(7):809-20 - PubMed
  38. Urology. 2006 Feb;67(2):440-6 - PubMed
  39. Hypertension. 2002 Feb;39(2):258-63 - PubMed

Publication Types